

Press release May 4, 2005

Professor John Sjögren new board member of Orexo AB

At Orexo's Annual General Meeting on April 20, 2005, Professor John Sjögren was elected new member of the Board of Directors. John Sjögren has many years of experience in drug development within Astra Hässle and unique knowledge in pharmaceuticals – the science of the delivery of pharmaceutical substances for the most effective therapeutic impact.

“Orexo’s successes are built on a combination of creativity, expertise and the ability to deliver,” says Zsolt Lavotha, President and CEO, Orexo AB. “This is a description that also fits Professor Sjögren very well and it is particularly pleasing that we can link his experience and expertise to the company at a time when Orexo’s pace of development and expansion is high.”

During the years 1973-1999, John Sjögren served as Adjunct Professor in Industrial Pharmacy at the department of Pharmaceutics at Uppsala University. During 1959-1994, he held various executive positions for Astra Hässle’s pharmaceutical research and was a member of the company’s management group from 1984 through 1998.

Professor John Sjögren has conducted internationally renowned research in the areas of pharmaceutical technology and biopharmaceutics, that is, how drug substances are assimilated and distributed in the body. He has particularly studied tablet formulation processes and technical properties of excipients as well as the formulation principles and biopharmaceutic methodology for evaluation of tablet preparations.

Professor Christer Nyström, one of Orexo’s founders and Board members since 1995, resigned from the Board.

For further information, please contact:

Zsolt Lavotha, President & CEO, Orexo AB
+46 (0)18 780 88 00. E-mail: zsolt.lavotha@orexo.se

Johan Tamsen, Corporate Communications
+46 (0)733 25 40 10, E-mail: johan.tamsen@orexo.se

To the editors

About Orexo

Orexo is a product focused drug delivery company that develops proprietary pharmaceuticals to address areas of unmet therapeutic need. Orexo exploits its multidisciplinary capabilities to assess areas of therapeutic need that can be met by developing proprietary pharmaceuticals based on well documented pharmacologically active compounds that incorporate Orexo’s proprietary drug delivery technologies.

The Company has commercialized one product, three product candidates in the clinical phase – where of one is out-licensed in North America and Japan – two product candidates in the formulation development phase and one project at an early research stage of development.

www.orexo.se

About drug delivery

Drug delivery is about finding methods to make the active component of a drug to function in the optimal manner through new preparations or formulations. Many of the pharmaceuticals sold today have shortcomings – for example, they may be slow-acting, product side-effects, require frequent administration in high dosages, or perhaps can only be injected. This is why the demand for new procedures that can enhance treatment efficiency is increasing sharply. Approximately one of five drugs of the 200 best-selling prescription drugs in the US has been improved through drug delivery.